Claire McDaniel
Interventional Cardiology · Gilbert, AZNPI 1700467958
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Kestra Medical Technology Services, Inc. at 27.1% of the total. 2025 is the largest year on record at $737, 7.6 times the $97 reported in 2021. That places this record below the midpoint for interventional cardiology clinicians in AZ, where the typical reported total is $10,657.
Across 137 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kestra Medical Technology Services, Inc.$645
- Abiomed$328
- AstraZeneca$317
- Amgen$273
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$171
- Boehringer Ingelheim$145
- plus $499 from 8 others
What the payments were for
- Food & beverage$2,27996%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kestra Medical Technology Services, Inc. | 53 | $645 |
| Abiomed | 3 | $328 |
| AstraZeneca | 14 | $317 |
| Amgen | 21 | $273 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $171 |
| Boehringer Ingelheim | 9 | $145 |
| Novartis | 7 | $123 |
| Edwards Lifesciences | 3 | $89 |
| Actelion Pharmaceuticals US, Inc. | 4 | $83 |
| Johnson & Johnson | 4 | $69 |
| Boston Scientific | 2 | $40 |
| Merck | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Kaleo, Inc. | 1 | $16 |
How this compares
$2,379 in reported general payments places this provider in the 15th percentile of 223 interventional cardiology providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $71,669 |
| Repatha SureclickEvolocumab | 13 | $15,435 |
| Rosuvastatin Calcium | 119 | $1,998 |
| Nifedipine ErNifedipine | 56 | $1,709 |
| Metoprolol Succinate | 101 | $1,266 |
| Ezetimibe | 40 | $1,049 |
| Labetalol Hcl | 40 | $965 |
| Atorvastatin Calcium | 94 | $945 |
| Valsartan | 38 | $921 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 17 | $759 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 34 | $757 |
| Enoxaparin Sodium | 16 | $639 |
| Amlodipine Besylate | 109 | $583 |
| Terazosin Hcl | 25 | $487 |
| Losartan Potassium | 51 | $467 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Gilbert
- Paul SorajjaPhoenix$1.1M
- Hursh NaikAvondale$781K
- Thomas WaggonerTucson$617K
- Timothy ByrnePhoenix$614K
- Haidar YassinPhoenix$434K
- Kapildeo LotunTucson$365K
- Azimuddin KhawajaPeoria$199K
- Rahul SharmaPeoria$195K
- Taral PatelScottsdale$171K
- Akil LoliPhoenix$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.